[{"id":"9816427f-a3a9-4c32-ab07-2e5ae738f6f8","acronym":"KRYSTAL-2","url":"https://clinicaltrials.gov/study/NCT04330664","created_at":"2021-01-18T20:58:21.593Z","updated_at":"2025-02-25T13:40:07.291Z","phase":"Phase 1","brief_title":"Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)","source_id_and_acronym":"NCT04330664 - KRYSTAL-2","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib) • batoprotafib (TNO155)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 04/07/2020","start_date":" 04/07/2020","primary_txt":" Primary completion: 07/29/2022","primary_completion_date":" 07/29/2022","study_txt":" Completion: 02/24/2025","study_completion_date":" 02/24/2025","last_update_posted":"2025-02-21"},{"id":"9c9bdd8c-7abe-4b3e-b585-0d05ef9a65f5","acronym":"CodeBreak101","url":"https://clinicaltrials.gov/study/NCT04185883","created_at":"2021-01-18T20:24:19.309Z","updated_at":"2025-02-25T15:11:23.343Z","phase":"Phase 1","brief_title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","source_id_and_acronym":"NCT04185883 - CodeBreak101","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • loperamide • zeluvalimab (AMG 404)"],"overall_status":"Recruiting","enrollment":" Enrollment 1200","initiation":"Initiation: 12/17/2019","start_date":" 12/17/2019","primary_txt":" Primary completion: 04/29/2026","primary_completion_date":" 04/29/2026","study_txt":" Completion: 03/13/2028","study_completion_date":" 03/13/2028","last_update_posted":"2025-02-13"},{"id":"45b9e4e8-9732-4ed9-b569-eae18917beb8","acronym":"KEYNOTE E27","url":"https://clinicaltrials.gov/study/NCT04956640","created_at":"2021-07-09T12:57:24.328Z","updated_at":"2025-02-25T16:16:26.190Z","phase":"Phase 1/2","brief_title":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","source_id_and_acronym":"NCT04956640 - KEYNOTE E27","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • erlotinib • carboplatin • Tyvyt (sintilimab) • Verzenio (abemaciclib) • pemetrexed • batoprotafib (TNO155) • temuterkib (LY3214996) • LY3295668 • olomorasib (LY3537982)"],"overall_status":"Recruiting","enrollment":" Enrollment 550","initiation":"Initiation: 07/19/2021","start_date":" 07/19/2021","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-01-28"},{"id":"1f12d403-2fb1-4336-8060-02027bae83cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04294160","created_at":"2021-01-18T20:50:10.771Z","updated_at":"2024-07-02T16:34:27.442Z","phase":"Phase 1","brief_title":"A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer","source_id_and_acronym":"NCT04294160","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001) • naporafenib (ERAS-254) • batoprotafib (TNO155) • rineterkib (LTT462)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 07/22/2020","start_date":" 07/22/2020","primary_txt":" Primary completion: 10/11/2024","primary_completion_date":" 10/11/2024","study_txt":" Completion: 10/11/2024","study_completion_date":" 10/11/2024","last_update_posted":"2024-06-11"},{"id":"1b39475a-c778-482c-b273-baa5f64197c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03114319","created_at":"2021-01-18T15:21:08.086Z","updated_at":"2024-07-02T16:34:59.273Z","phase":"Phase 1","brief_title":"Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03114319","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e batoprotafib (TNO155) • nazartinib (EGF816)"],"overall_status":"Recruiting","enrollment":" Enrollment 255","initiation":"Initiation: 05/26/2017","start_date":" 05/26/2017","primary_txt":" Primary completion: 06/11/2025","primary_completion_date":" 06/11/2025","study_txt":" Completion: 06/11/2025","study_completion_date":" 06/11/2025","last_update_posted":"2024-06-04"},{"id":"fa46a890-7098-41a4-a73e-faad6ef1e43e","acronym":"KontRASt-01","url":"https://clinicaltrials.gov/study/NCT04699188","created_at":"2021-01-19T20:50:07.332Z","updated_at":"2024-07-02T16:34:58.896Z","phase":"Phase 1/2","brief_title":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","source_id_and_acronym":"NCT04699188 - KontRASt-01","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001) • batoprotafib (TNO155) • opnurasib (JDQ443)"],"overall_status":"Recruiting","enrollment":" Enrollment 475","initiation":"Initiation: 02/24/2021","start_date":" 02/24/2021","primary_txt":" Primary completion: 01/08/2027","primary_completion_date":" 01/08/2027","study_txt":" Completion: 01/08/2027","study_completion_date":" 01/08/2027","last_update_posted":"2024-06-04"},{"id":"ce28c372-7763-4606-bef0-0f465abf3744","acronym":"","url":"https://clinicaltrials.gov/study/NCT04292119","created_at":"2021-01-18T20:49:43.053Z","updated_at":"2024-07-02T16:36:33.523Z","phase":"Phase 1/2","brief_title":"Lorlatinib Combinations in Lung Cancer","source_id_and_acronym":"NCT04292119","lead_sponsor":"Massachusetts General Hospital","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK rearrangement • ROS1 positive • ROS1 rearrangement","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • ROS1 positive • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • batoprotafib (TNO155)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 05/01/2020","start_date":" 05/01/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2021-03-10"}]